Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?
Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?
复制标题
DOI：
10.1152/ajpgi.00036.2015
复制
发表时间：
2015-11-15
期刊：
影响因子：
--
通讯作者：
Newsome PN
中科院分区：
文献类型：
--
作者：
Owen A;Newsome PN
仅在美国，终末期肝病每年就导致 30,000 人死亡，而且这一数字还在逐年增加。由于肝移植是目前唯一可用的治疗方法，因此对新疗法的需求很大。间充质干细胞（MSC）提供了治疗肝脏炎症损伤以及逆转慢性肝损伤后发生的一些变化的机会。 MSC 具有调节先天性和适应性免疫系统，以及抑制和促进效应炎症细胞凋亡的能力，因此在急性和慢性肝病中有许多治疗机会。本文批判性地评估了 MSC 在肝病中的潜在治疗作用，以及其应用于临床实践的障碍。
End-stage liver disease is responsible for 30,000 deaths per year in the United States alone, and it is continuing to increase every year. With liver transplantation the only curative treatment currently available, new therapies are in great demand. Mesenchymal stem cells (MSC) offer an opportunity to both treat liver inflammatory damage, as well as reverse some of the changes that occur following chronic liver injury. With the ability to regulate both the innate and adaptive immune system, as well as both inhibit and promote apoptosis of effector inflammatory cells, there are numerous therapeutic opportunities for MSC in acute and chronic liver disease. This article critically appraises the potential therapeutic roles of MSC in liver disease, as well as the barriers to their adoption into clinical practice.